Mol Dev Q1 Organic Revs Up 6 Percent; Will New Launch Help Imaging Sales? | GenomeWeb

Increasing sales in its drug-discovery and life-science research product lines helped Molecular Devices' first-quarter revenues grow 6 percent organically, but the company's acquisition of Axon, sealed last July, boosted total receipts by 43 percent, the company said last week.

Molecular Devices, which said net profits in the period grew 57 percent, also said it will launch a new imaging system and software next month in order to give its Discovery-1 and ImageXpress platforms a boost in the marketplace.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.